{
    "clinical_study": {
        "@rank": "161547", 
        "arm_group": [
            {
                "arm_group_label": "Ademethionine", 
                "arm_group_type": "Experimental", 
                "description": "ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for  4 weeks."
            }, 
            {
                "arm_group_label": "Polyene Phosphatidyl choline", 
                "arm_group_type": "Active Comparator", 
                "description": "Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy and safety S-adenosyl-l-methionine in alcoholic hepatitis with\n      cholestasis."
        }, 
        "brief_title": "Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis, Alcoholic", 
        "condition_browse": {
            "mesh_term": [
                "Cholestasis", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Alcoholic"
            ]
        }, 
        "detailed_description": {
            "textblock": "randomize first time  for core treatment stage for 6 weeks, then randomized second time for\n      extend treatment for 42 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index range 19-30kg/m2\n\n          -  Alcohol Drinking history more than 5 years, for male \u2265 40g/ day, for female \u2265 20g/\n             day;\n\n          -  STB from 2 to 10X ULN;\n\n          -  ALP>1.5X ULN or GGT>3X ULN\n\n        Exclusion Criteria: any one of below,\n\n          -  active virus hepatitis, or anti-HIV(+)\n\n          -  exclude other hepatic disease: non-alcoholic fatty liver, drug-induced liver injury,\n             autoimmune hepatitis( AMA/ANA>1:100), Wilson disease,  hemochromatosis or other\n             hepatic disease; obstructive cholestasis\n\n          -  other non-hepatic diseases caused  jaundice\n\n          -  primary hepatic carcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024295", 
            "org_study_id": "XMX-AH-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ademethionine", 
                "description": "ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.", 
                "intervention_name": "Ademethionine", 
                "intervention_type": "Drug", 
                "other_name": "ademethionine  for 6 weeks"
            }, 
            {
                "arm_group_label": "Polyene Phosphatidyl choline", 
                "description": "Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.", 
                "intervention_name": "Polyene Phosphatidyl choline", 
                "intervention_type": "Drug", 
                "other_name": "Polyene Phosphatidyl choline  for 6 weeks"
            }, 
            {
                "arm_group_label": [
                    "Ademethionine", 
                    "Polyene Phosphatidyl choline"
                ], 
                "description": "after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks", 
                "intervention_name": "Ademethionine", 
                "intervention_type": "Drug", 
                "other_name": "stage 2, ademethionine for 42 weeks."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Choline", 
                "Polyene phosphatidylcholine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jun.cheng.ditan@gmail.com", 
                    "last_name": "Jun Cheng", 
                    "phone": "8610-84322566"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100015"
                    }, 
                    "name": "Beijing Ditan Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jun Cheng"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100015"
                    }, 
                    "name": "Jun Cheng"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis", 
        "other_outcome": {
            "description": "Liver biopsy is not demanded", 
            "measure": "Liver biopsy", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "overall_contact": {
            "email": "jun.cheng.ditan@gmail.com", 
            "last_name": "Jun Cheng", 
            "phone": "8610-84322000"
        }, 
        "overall_official": {
            "affiliation": "Beijing Ditan Hospital affiliated ffiated to Capital Medical University", 
            "last_name": "Jun Cheng", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "response rate means percentage of subjects whose serum total bilirubin values declined from baseline over 30%", 
            "measure": "response rate of serum total bilirubin", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "level of serum direct bilirubin", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }, 
            {
                "measure": "level of serum bile acids", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }, 
            {
                "measure": "level of glutamic pyruvic transaminase", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }, 
            {
                "measure": "level of glutamic oxaloacetic transaminase", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }, 
            {
                "measure": "level of alkaline phosphatase", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }, 
            {
                "measure": "level of gamma-glutamyl transpeptidase", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }, 
            {
                "measure": "level of hyaluronic acid", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks and 48 weeks"
            }
        ], 
        "source": "Zhejiang Hisun Pharmaceutical Co. Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang Hisun Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}